News|Articles|February 17, 2016

Capsugel and Pulmatrix Collaborate on Pulmonary Disease Treatments

The collaboration will allow the companies to develop and manufacture novel inhaled therapeutics.

Capsugel and Pulmatrix formed a collaboration to develop and manufacture novel inhaled therapeutics for pulmonary diseases, according to a Feb. 16, 2016 press announcement from the companies. The agreement provides Capsugel exclusive rights to manufacture clinical trial and commercial batches of iSPERSE -based inhaled therapeutic candidates being developed by Pulmatrix and its potential development partners.

iSPERSE is a dense and dispersible-engineered particle technology that enables pulmonary delivery of drugs with high delivery efficiency, dose reproducibility, and flow-rate independence. Several products leveraging the iSPERSE platform are in development, two of which are a clinical stage bronchodilator (PUR0200) for chronic obstructive pulmonary disease, and an inhaled anti-fungal (PUR1900) for cystic fibrosis.

“This collaboration provides us with access to Capsugel’s spray dry technology, scale-up capabilities, and state-of-the-art equipment to support our growing pipeline of internal and partnered development programs,” said Robert Clarke, PhD, CEO of Pulmatrix in a press announcement.

Source: Capsugel


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.